Omada Health Earnings Call Highlights Profitable Growth
Omada Health, Inc. ((OMDA)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Omada Health’s latest earnings call struck a confident tone, highlighting a breakout 2025 marked by rapid growth, scaling membership, and the company’s first taste of GAAP profitability. Management balanced this optimism with cautious 2026 guidance, emphasizing conservative assumptions around new products and market uncertainty, yet pointing to durable momentum and improving unit economics.
Explosive Revenue Growth and Expanding Member Scale
Omada delivered full-year 2025 revenue of $260 million, up 53% year over year, with Q4 revenue of $76 million rising 58%. Membership scaled sharply to 886,000 by year-end, a 55% increase, as the company added 314,000 net new members in 2025 including 55,000 in Q4, underscoring strong demand for its digital care programs.
Profitability Milestones and Strengthening Cash Position
The company posted its first-ever quarter of GAAP net income in Q4 2025, generating $5 million of profit. For the full year, Omada produced $6 million of adjusted EBITDA with a 2% margin, converted 40% of incremental revenue into EBITDA, generated positive operating cash flow, and ended 2025 with $222 million in cash and no debt on the balance sheet.
Record Margin Expansion Driven by Scale and Efficiency
Adjusted gross margin in Q4 reached a record 73%, up 320 basis points from a year earlier, while full-year adjusted gross margin improved to 68%, up 450 basis points. GAAP gross margin reached 71% in Q4 and 66% for the year as operating leverage, care-team optimization, and AI-enabled efficiencies reduced costs relative to revenue.
Commercial Traction and Growing Reach Across Channels
Omada’s commercial footprint expanded as estimated covered and eligible lives grew to more than 25 million, reflecting an increase of over 5 million lives. The company reported strong performance across distribution partners, including pharmacy benefit managers and a large new channel partner, while deepening multi-condition adoption among existing customers.
Scaling GLP-1 Care With Differentiated Outcomes
The GLP-1 Care Track scaled beyond 150,000 members after adding more than 100,000 participants in 2025, cementing it as a major growth pillar. Evidence shared on the call showed members staying on GLP-1s achieved about 18% average weight loss versus roughly 12% in real-world settings without structured support, and those discontinuing largely maintained weight at one year.
Product and AI Innovation Across the Care Platform
Management highlighted a slate of new offerings, including GLP-1 prescribing, the GLP-1 Flex Care model, a cholesterol program, the OmadaSpark AI assistant, and the Meal Map nutrition tool. AI has been integrated into care summarization, coding, and personalization, leveraging a proprietary dataset of tens of millions of messages and billions of data points to improve outcomes and efficiency.
Clinical Validation and Program Performance
Omada published 30 peer-reviewed papers during the year, including musculoskeletal data showing lower utilization and costs versus in-person physical therapy. Across conditions, weight-health revenue grew more than 50%, while diabetes and hypertension revenue each increased roughly 45% or more, with over half of members still engaging monthly at both 12 and 24 months.
Expense Discipline and Operating Leverage
Adjusted operating expenses rose 24% to $170 million in 2025, well below the 53% revenue growth, highlighting emerging operating leverage. In Q4, GAAP operating expenses increased 28% year over year as the company continued to support scale and invest in product innovation, but costs grew slower than the topline.
Guidance Signals Growth Deceleration From 2025’s Surge
For 2026, management guided revenue to $312–$322 million, implying about 22% growth at the midpoint, a notable slowdown from 2025’s 53% expansion. The company stressed that guidance assumes no meaningful uplift from GLP-1 prescribing, GLP-1 Flex Care, or cholesterol and no major conversion gains, signaling a deliberately conservative outlook.
Full-Year GAAP Loss Underscores Early Stage of Profitability
Despite the profitable Q4, Omada reported a full-year 2025 GAAP net loss of $13 million, an improvement from a $47 million loss in 2024 but still in the red. This gap underscores that sustained profitability is nascent, with the company needing further scale and margin gains before earnings become consistently positive.
Seasonal and Near-Term Margin Pressure in Q1
Management expects Q1 2026 revenue to be roughly flat with Q4, even after adjusting for a one-time true-up, as it is the heaviest quarter for new enrollments and device shipments. Those upfront device and care-team labor costs will pressure margins early in the year before improving as these new members ramp and generate recurring revenue.
Impact of a One-Time Q4 Revenue True-Up
Q4 results included a one-time $2 million transaction and revenue true-up with a large partner, lifting revenue, gross profit, and adjusted EBITDA. Since this benefit will not repeat, investors were cautioned that sequential comparisons into Q1 will appear softer, masking the underlying run-rate performance.
Market Uncertainty Around GLP-1 Coverage
The GLP-1 opportunity is tempered by uncertainty, with management estimating that about 55% of large employers still do not cover these drugs for obesity. Budget pressures, evolving benefit designs, and changing pricing and utilization dynamics have led Omada to introduce GLP-1 Flex Care, but adoption levels and long-term economics remain early and unproven.
New Products Early in Their Revenue Contribution
New initiatives such as GLP-1 prescribing, GLP-1 Flex Care, and the cholesterol program are in early stages and currently contribute little to revenue. Management indicated that broader rollouts, including a wider cholesterol launch expected in 2027, limit near-term upside and thus were largely excluded from the 2026 financial outlook.
Guidance and Long-Term Targets Frame the Road Ahead
For 2026, Omada expects revenue of $312–$322 million and adjusted EBITDA of $7–$15 million, with a midpoint around $317 million and $11 million respectively, modestly improving profitability from 2025. The company reiterated long-term goals of maintaining adjusted gross margins above 70% and driving adjusted EBITDA margins above 20% as it scales from roughly 886,000 members and more than 25 million covered lives.
Omada’s earnings call painted a picture of a company entering a new phase of scale and profitability while still managing significant market and execution risks. With strong 2025 growth, improving margins, and a growing AI-driven product suite, investors are being asked to weigh near-term growth deceleration and GLP-1 uncertainty against a longer-term thesis of durable, high-margin digital care at scale.
